Eintrag weiter verarbeiten
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | Journal of Clinical Oncology, 25, 2007, 18_suppl, S. 8081-8081 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. |
|---|---|
| author |
Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. |
| spellingShingle |
Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. Journal of Clinical Oncology CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients Cancer Research Oncology |
| author_sort |
zhai, l. |
| spelling |
Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8081 <jats:p> 8081 </jats:p><jats:p> Background: THP-ADM (Pirarubicin) has potential to replace conventional ADM (Adriamycin) because of less severe toxicities. However, only a few studies have compared the long-term outcome between patients receiving the two drugs. A Japanese trial (JGTLE) shows the CR rate of THP-COP group was greater than CHOP group in elderly T-cell Non-Hodgkin's Lymphoma (NHL) patients. The current study was aimed at comparing the long-term outcome and toxicities between NHL patients receiving CHOP and THP-COP regimens within similar age-groups and pathological sub-types. Methods: 505 previously untreated NHL patients receiving either standard CHOP or THP-COP regimen (cyclophosphamide 750 mg/m<jats:sup>2</jats:sup>, doxorubicin or pirarubicin 50 mg/m<jats:sup>2</jats:sup>, vincristine 1.4 mg/m<jats:sup>2</jats:sup>and prednisone 40 mg/m<jats:sup>2</jats:sup> for 5 days) were enrolled. Results: Patients’ characteristics between CHOP group(n=279) and THP-COP (n=228) group were well balanced. There were no differences in CR rate (54.8% vs. 54.0%, p=0.85) and response rate (82.1% vs. 84.1%, p=0.55). With a median follow-up of 59.7months, survival rate was similar (5-year OS: 56.7% vs. 55.8%, 5-year PFS: 43.5% vs. 47.3%, 5-year DFS: 54.0% vs. 54.7%). The incidence of cardiotoxicity(myocardial dysfunction and arrhythmia)was almost the same (10.0% vs10.2 %; P=0.958). Less Alopecia (39.1% vs. 28.8%, p= 0.015)and gastrointestinal toxicities(63.1% vs. 50.0%, p=0.003) were observed in THP-COP group. No differences between the two groups were observed within different pathological subtypes (B-cell subtype: CR rate 58.2% vs. 56.7%, 5-year OS 59.2% vs. 60.0%; T-cell subtype: CR rate 47.0% vs. 45.5%, 5-year OS 50.5% vs. 43.4%) and age-groups (<60 years group: CR rate 51.6% vs. 53.7%, p= 0.684; 5y OS 58.9% vs.61.1%, p= 0.570; =60 years group: CR rate 67.9% vs. 54.8 %, p= 0.148; 5y OS 48.0% vs. 42.1 %, p= 0.314). In the 33 elderly patients of T-cell subtype, CR rates were almost the same. (73.7% vs. 42.9%, p=0.073). Conclusions: The long-term outcome of NHL patients receiving THP-COP is similar to those receiving CHOP within similar age groups and pathologic subtypes. Cardiotoxicity occurs at a similar rate in both groups, while a lower incidence of alopecia and gastrointestinal toxicities was observed in THP-COP group. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2007.25.18_suppl.8081 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNy4yNS4xOF9zdXBwbC44MDgx |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNy4yNS4xOF9zdXBwbC44MDgx |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2007 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2007 |
| issn |
1527-7755 0732-183X |
| issn_str_mv |
1527-7755 0732-183X |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
zhai2007chopcomparedtothpcopregimenlongtermoutcomeinchinesenonhodgkinlymphomanhlpatients |
| publishDateSort |
2007 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_unstemmed |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_full |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_fullStr |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_full_unstemmed |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_short |
CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_sort |
chop compared to thp-cop regimen: long-term outcome in chinese non-hodgkin lymphoma (nhl) patients |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8081 |
| publishDate |
2007 |
| physical |
8081-8081 |
| description |
<jats:p> 8081 </jats:p><jats:p> Background: THP-ADM (Pirarubicin) has potential to replace conventional ADM (Adriamycin) because of less severe toxicities. However, only a few studies have compared the long-term outcome between patients receiving the two drugs. A Japanese trial (JGTLE) shows the CR rate of THP-COP group was greater than CHOP group in elderly T-cell Non-Hodgkin's Lymphoma (NHL) patients. The current study was aimed at comparing the long-term outcome and toxicities between NHL patients receiving CHOP and THP-COP regimens within similar age-groups and pathological sub-types. Methods: 505 previously untreated NHL patients receiving either standard CHOP or THP-COP regimen (cyclophosphamide 750 mg/m<jats:sup>2</jats:sup>, doxorubicin or pirarubicin 50 mg/m<jats:sup>2</jats:sup>, vincristine 1.4 mg/m<jats:sup>2</jats:sup>and prednisone 40 mg/m<jats:sup>2</jats:sup> for 5 days) were enrolled. Results: Patients’ characteristics between CHOP group(n=279) and THP-COP (n=228) group were well balanced. There were no differences in CR rate (54.8% vs. 54.0%, p=0.85) and response rate (82.1% vs. 84.1%, p=0.55). With a median follow-up of 59.7months, survival rate was similar (5-year OS: 56.7% vs. 55.8%, 5-year PFS: 43.5% vs. 47.3%, 5-year DFS: 54.0% vs. 54.7%). The incidence of cardiotoxicity(myocardial dysfunction and arrhythmia)was almost the same (10.0% vs10.2 %; P=0.958). Less Alopecia (39.1% vs. 28.8%, p= 0.015)and gastrointestinal toxicities(63.1% vs. 50.0%, p=0.003) were observed in THP-COP group. No differences between the two groups were observed within different pathological subtypes (B-cell subtype: CR rate 58.2% vs. 56.7%, 5-year OS 59.2% vs. 60.0%; T-cell subtype: CR rate 47.0% vs. 45.5%, 5-year OS 50.5% vs. 43.4%) and age-groups (<60 years group: CR rate 51.6% vs. 53.7%, p= 0.684; 5y OS 58.9% vs.61.1%, p= 0.570; =60 years group: CR rate 67.9% vs. 54.8 %, p= 0.148; 5y OS 48.0% vs. 42.1 %, p= 0.314). In the 33 elderly patients of T-cell subtype, CR rates were almost the same. (73.7% vs. 42.9%, p=0.073). Conclusions: The long-term outcome of NHL patients receiving THP-COP is similar to those receiving CHOP within similar age groups and pathologic subtypes. Cardiotoxicity occurs at a similar rate in both groups, while a lower incidence of alopecia and gastrointestinal toxicities was observed in THP-COP group. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| container_issue |
18_suppl |
| container_start_page |
8081 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
25 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792324805225086981 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:54:55.711Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=CHOP+compared+to+THP-COP+regimen%3A+Long-term+outcome+in+Chinese+non-Hodgkin+lymphoma+%28NHL%29+patients&rft.date=2007-06-20&genre=article&issn=1527-7755&volume=25&issue=18_suppl&spage=8081&epage=8081&pages=8081-8081&jtitle=Journal+of+Clinical+Oncology&atitle=CHOP+compared+to+THP-COP+regimen%3A+Long-term+outcome+in+Chinese+non-Hodgkin+lymphoma+%28NHL%29+patients&aulast=Lin&aufirst=T.+Y.&rft_id=info%3Adoi%2F10.1200%2Fjco.2007.25.18_suppl.8081&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792324805225086981 |
| author | Zhai, L., Cheng, C., Niraula, S., Huang, Y., Li, Z. M., Wang, S. S., Huang, H. Q., Lin, T. Y. |
| author_facet | Zhai, L., Cheng, C., Niraula, S., Huang, Y., Li, Z. M., Wang, S. S., Huang, H. Q., Lin, T. Y., Zhai, L., Cheng, C., Niraula, S., Huang, Y., Li, Z. M., Wang, S. S., Huang, H. Q., Lin, T. Y. |
| author_sort | zhai, l. |
| container_issue | 18_suppl |
| container_start_page | 8081 |
| container_title | Journal of Clinical Oncology |
| container_volume | 25 |
| description | <jats:p> 8081 </jats:p><jats:p> Background: THP-ADM (Pirarubicin) has potential to replace conventional ADM (Adriamycin) because of less severe toxicities. However, only a few studies have compared the long-term outcome between patients receiving the two drugs. A Japanese trial (JGTLE) shows the CR rate of THP-COP group was greater than CHOP group in elderly T-cell Non-Hodgkin's Lymphoma (NHL) patients. The current study was aimed at comparing the long-term outcome and toxicities between NHL patients receiving CHOP and THP-COP regimens within similar age-groups and pathological sub-types. Methods: 505 previously untreated NHL patients receiving either standard CHOP or THP-COP regimen (cyclophosphamide 750 mg/m<jats:sup>2</jats:sup>, doxorubicin or pirarubicin 50 mg/m<jats:sup>2</jats:sup>, vincristine 1.4 mg/m<jats:sup>2</jats:sup>and prednisone 40 mg/m<jats:sup>2</jats:sup> for 5 days) were enrolled. Results: Patients’ characteristics between CHOP group(n=279) and THP-COP (n=228) group were well balanced. There were no differences in CR rate (54.8% vs. 54.0%, p=0.85) and response rate (82.1% vs. 84.1%, p=0.55). With a median follow-up of 59.7months, survival rate was similar (5-year OS: 56.7% vs. 55.8%, 5-year PFS: 43.5% vs. 47.3%, 5-year DFS: 54.0% vs. 54.7%). The incidence of cardiotoxicity(myocardial dysfunction and arrhythmia)was almost the same (10.0% vs10.2 %; P=0.958). Less Alopecia (39.1% vs. 28.8%, p= 0.015)and gastrointestinal toxicities(63.1% vs. 50.0%, p=0.003) were observed in THP-COP group. No differences between the two groups were observed within different pathological subtypes (B-cell subtype: CR rate 58.2% vs. 56.7%, 5-year OS 59.2% vs. 60.0%; T-cell subtype: CR rate 47.0% vs. 45.5%, 5-year OS 50.5% vs. 43.4%) and age-groups (<60 years group: CR rate 51.6% vs. 53.7%, p= 0.684; 5y OS 58.9% vs.61.1%, p= 0.570; =60 years group: CR rate 67.9% vs. 54.8 %, p= 0.148; 5y OS 48.0% vs. 42.1 %, p= 0.314). In the 33 elderly patients of T-cell subtype, CR rates were almost the same. (73.7% vs. 42.9%, p=0.073). Conclusions: The long-term outcome of NHL patients receiving THP-COP is similar to those receiving CHOP within similar age groups and pathologic subtypes. Cardiotoxicity occurs at a similar rate in both groups, while a lower incidence of alopecia and gastrointestinal toxicities was observed in THP-COP group. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> |
| doi_str_mv | 10.1200/jco.2007.25.18_suppl.8081 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAwNy4yNS4xOF9zdXBwbC44MDgx |
| imprint | American Society of Clinical Oncology (ASCO), 2007 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2007 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1527-7755, 0732-183X |
| issn_str_mv | 1527-7755, 0732-183X |
| language | English |
| last_indexed | 2024-03-01T11:54:55.711Z |
| match_str | zhai2007chopcomparedtothpcopregimenlongtermoutcomeinchinesenonhodgkinlymphomanhlpatients |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 8081-8081 |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Zhai, L. Cheng, C. Niraula, S. Huang, Y. Li, Z. M. Wang, S. S. Huang, H. Q. Lin, T. Y. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8081 <jats:p> 8081 </jats:p><jats:p> Background: THP-ADM (Pirarubicin) has potential to replace conventional ADM (Adriamycin) because of less severe toxicities. However, only a few studies have compared the long-term outcome between patients receiving the two drugs. A Japanese trial (JGTLE) shows the CR rate of THP-COP group was greater than CHOP group in elderly T-cell Non-Hodgkin's Lymphoma (NHL) patients. The current study was aimed at comparing the long-term outcome and toxicities between NHL patients receiving CHOP and THP-COP regimens within similar age-groups and pathological sub-types. Methods: 505 previously untreated NHL patients receiving either standard CHOP or THP-COP regimen (cyclophosphamide 750 mg/m<jats:sup>2</jats:sup>, doxorubicin or pirarubicin 50 mg/m<jats:sup>2</jats:sup>, vincristine 1.4 mg/m<jats:sup>2</jats:sup>and prednisone 40 mg/m<jats:sup>2</jats:sup> for 5 days) were enrolled. Results: Patients’ characteristics between CHOP group(n=279) and THP-COP (n=228) group were well balanced. There were no differences in CR rate (54.8% vs. 54.0%, p=0.85) and response rate (82.1% vs. 84.1%, p=0.55). With a median follow-up of 59.7months, survival rate was similar (5-year OS: 56.7% vs. 55.8%, 5-year PFS: 43.5% vs. 47.3%, 5-year DFS: 54.0% vs. 54.7%). The incidence of cardiotoxicity(myocardial dysfunction and arrhythmia)was almost the same (10.0% vs10.2 %; P=0.958). Less Alopecia (39.1% vs. 28.8%, p= 0.015)and gastrointestinal toxicities(63.1% vs. 50.0%, p=0.003) were observed in THP-COP group. No differences between the two groups were observed within different pathological subtypes (B-cell subtype: CR rate 58.2% vs. 56.7%, 5-year OS 59.2% vs. 60.0%; T-cell subtype: CR rate 47.0% vs. 45.5%, 5-year OS 50.5% vs. 43.4%) and age-groups (<60 years group: CR rate 51.6% vs. 53.7%, p= 0.684; 5y OS 58.9% vs.61.1%, p= 0.570; =60 years group: CR rate 67.9% vs. 54.8 %, p= 0.148; 5y OS 48.0% vs. 42.1 %, p= 0.314). In the 33 elderly patients of T-cell subtype, CR rates were almost the same. (73.7% vs. 42.9%, p=0.073). Conclusions: The long-term outcome of NHL patients receiving THP-COP is similar to those receiving CHOP within similar age groups and pathologic subtypes. Cardiotoxicity occurs at a similar rate in both groups, while a lower incidence of alopecia and gastrointestinal toxicities was observed in THP-COP group. </jats:p><jats:p> No significant financial relationships to disclose. </jats:p> CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients Journal of Clinical Oncology |
| spellingShingle | Zhai, L., Cheng, C., Niraula, S., Huang, Y., Li, Z. M., Wang, S. S., Huang, H. Q., Lin, T. Y., Journal of Clinical Oncology, CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients, Cancer Research, Oncology |
| title | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_full | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_fullStr | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_full_unstemmed | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_short | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| title_sort | chop compared to thp-cop regimen: long-term outcome in chinese non-hodgkin lymphoma (nhl) patients |
| title_unstemmed | CHOP compared to THP-COP regimen: Long-term outcome in Chinese non-Hodgkin lymphoma (NHL) patients |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8081 |